Table 3 Pooled diagnostic accuracy

From: The association between abnormal microRNA-10b expression and cancer risk: a meta-analysis

 

Cancer vs. Non-cancer

Tissue-based miRNA

Nor-tissue-based miRNA

Digestive system cancer

Nor-digestive system cancer

No. of studies

13

10

3

4

9

Cancer Group (No./total No.)

211/436

165/253

46/183

79/135

132/301

Control Group (No./total No.)

6/179

2/74

4/105

6/93

0/86

OR(95% CI)

32.80 (11.90–90.37)a

10.71 (3.48–32.93)

8.86 (2.93–26.88)

26.37 (3.21– 216.41)a

33.97 (11.98– 96.32)

Heterogeneityb (p)

21.41 (0.05)

14.43 (0.11)

0.91 (0.63)

10.82 (0.01)

9.84 (0.28)

AUC (95% CI)

0.98 (0.96–0.99)

0.99 (0.98– 1.00)

0.50 (0.09–0.91)

0.93 (0.90– 0.95)

0.50 (0.09– 0.91)

SEN (95% CI)

0.98 (0.89–0.99)

0.99 (0.76– 1.00)

-

0.93 (0.84– 0.97)

-

Heterogeneityb (p)

33.16 (0.00)

16.29 (0.06)

-

4.15 (0.26)

-

SPE (95% CI)

0.62 (0.39–0.82)

0.655 (0.36– 0.87)

-

0.67 (0.30– 0.90)

-

Heterogeneityb (p)

145.83 (0.00)

113.01 (0.00)

-

33.5 (0.00)

-

PLR(95% CI)

2.63 (1.44–4.82)

2.891 (1.29– 6.49)

-

2.77 (1.00– 7.70)

-

Heterogeneityb (p)

240.04 (0.00)

242.68 (0.00)

0.00 (1.0)

34.61 (0.00)

0.00 (1.0)

NLR(95% CI)

0.02 (0.002–0.172)

0.003 (0.00– 0.42)

-

0.11 (0.04– 0.29)

-

Heterogeneityb (p)

32.93 (0.00)

35.66 (0.00)

0.00 (1.0)

4.61 (0.20)

0.00 (1.0)

DOR(95% CI)

133.145 (13.21–1341.87)

1035.07 (7.52–1.4e+05)

-

25.54 (4.15–157.01)

-

Heterogeneityb (p)

14.537 (0.000)

14.249 (0.00)

-

6.24 (0.02)

-

  1. aSignificant heterogeneity: the random-effects model was chosen to summarize the result; bQ-value.
  2. OR-odds ratio; AUC-area under the curve; SEN-sensitivity; SPE-specificity; PLR-positive likelihood ratio; NLR-negative likelihood ratio; DOR-diagnostic odds ratio.